Brief: Tenaya Therapeutics Announces 2026 Strategic Priorities
09/01/2026 14:01
Jan 9 (Reuters) - Tenaya Therapeutics Inc TNYA.O: TENAYA THERAPEUTICS ANNOUNCES 2026 STRATEGIC PRIORITIES AND ANTICIPATED MILESTONES TENAYA THERAPEUTICS INC - RAISED $60 MILLION IN 4Q25 TO SUPPORT RUNWAY THROUGH MID-2027 TENAYA THERAPEUTICS - EXPECTS TO REPORT ONE-YEAR COHORT 1 DATA & EARLY COHORT 2 DATA FROM RIDGE-1 STUDY OF TN-401 FOR PKP2-ASSOCIATED ARVC IN H1 2026 TENAYA THERAPEUTICS INC - PLANS TO PURSUE REGULATORY ALIGNMENT ON TN-201 IN 2026 TENAYA THERAPEUTICS INC - PLANS TO PURSUE REGULATORY ALIGNMENT ON TN-401 IN H2 2026 Source text: ID:nGNX5xRRdC Further company coverage: TNYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027